Viatris Innovation

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Viatris Innovation sits in the top decile of US sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count).

11 total trials 2 currently recruiting 8 completed early-phase tilt top decile by trial count

Viatris Innovation: 11 sponsored US clinical trials, 2 recruiting.

Viatris Innovation sponsors 11 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 8 completed. 3 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Lupus Erythematosus, Systemic, with 3 trials.

Top-decile sponsor footprint

Viatris Innovation ranks in the top decile of sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

11 total, page 1 of 1

RECRUITING Phase 3

A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment

NCT07201129
RECRUITING Phase 3

A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus

NCT05648500
ACTIVE NOT RECRUITING Phase 3

A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus

NCT05672576
COMPLETED Phase 1

A Trial to Compare What the Body Does to Selatogrel and the Effect of Selatogrel in Japanese and Caucasian Healthy Participants

NCT07133191
COMPLETED Phase 1

A Comparative Study of Selatogrel (ACT-246475) Formulations in Healthy Subjects

NCT04557280
COMPLETED Phase 1

Single Oral Dose of 4 mg Cenerimod in Healthy Japanese and Caucasian Subjects

NCT04052360
COMPLETED Phase 2

Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus

NCT03742037
COMPLETED Phase 2

A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Coronary Artery Disease

NCT03384966
COMPLETED Phase 1

A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjects

NCT03430661
COMPLETED Phase 1

A Study Conducted in Healthy Male Subjects to Investigate the Safety and Tolerability of AC-76, Its Fate in the Body, and Its Effect on the Body

NCT03173625
COMPLETED Phase 1

Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus

NCT02472795

Phase Distribution

PhaseTrial count
Phase 1 6
Phase 2 2
Phase 3 3

Therapeutic Areas

Lupus Erythematosus, Systemic 3
Nephritis, Lupus 1
Healthy Volunteers 1

What is open in the Viatris Innovation pipeline

2 recruiting of 11 indexed (18% open); 8 completed (73%).

Phase mix: 3 late (III/IV) vs 8 early (I/II) (early-phase heavy).

Top condition: Lupus Erythematosus, Systemic (3 trials), 2 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Viatris Innovation: open-pipeline peers nationwide

Peers matched on 11 registered trials and 18% open enrollment, not the therapeutic-area sidebar.

Viatris Innovation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 10.910.91111.1 0%5%10%15%20% Total trials Recruiting share Viatris InnovationAderans Research InstituteAegerion PharmaceuticalsAllena PharmaceuticalsAOBiomeBurke Medical Research InstituteGrand Valley State UniversityImunonInventisBio Co.
Viatris Innovation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Viatris Innovation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 11 trials (± recruiting share)

Sponsors near 18% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Viatris Innovation page

11 registered trials is a research-attention snapshot, not an endorsement of Viatris Innovation or any single study.

  • 2 of Viatris Innovation's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Lupus Erythematosus, Systemic is the condition Viatris Innovation studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Lupus Erythematosus, Systemic trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Viatris Innovation pipeline card: 11 registered trials from official public datasets.Report a data error.